{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:48:38Z","timestamp":1786978118095,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1002\/jps.21282","type":"journal-article","created":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T13:46:21Z","timestamp":1202305581000},"page":"3691-3699","source":"Crossref","is-referenced-by-count":52,"title":["Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Acetazolamide"],"prefix":"10.1016","volume":"97","author":[{"given":"G.E.","family":"Granero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Longhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.E.","family":"Junginger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.K.","family":"Midha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stavchansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.B.","family":"Dressman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Barends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/jps.21282_bb0010","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/jps.20131","article-title":"Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol","volume":"93","author":"Vogelpoel","year":"2004","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21282_bb0015","unstructured":"WHO, 2006. Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability. Technical Report Series, No937, 40th Report, Annex 7http:\/\/whqlibdoc.who.int\/trs\/WHO_TRS_937_eng.pdf4."},{"key":"10.1002\/jps.21282_bb0020","unstructured":"Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. Technical Report Series, No937, 40th Report, Annex 8http:\/\/whqlibdoc.who.int\/trs\/WHO_TRS_937_eng.pdf."},{"key":"10.1002\/jps.21282_bb0025","series-title":"Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solidoral dosage forms based on a Biopharmaceutics Classification System","year":"2000"},{"key":"10.1002\/jps.21282_bb0030","unstructured":"CPMP, 2001. Note for guidance on the investigation of bioavailability and bioequivalence.http:\/\/www.emea.eu.int\/pdfs\/human\/ewp\/140198en.pdf."},{"key":"10.1002\/jps.21282_bb0035","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/jps.20343","article-title":"Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride","volume":"94","author":"Verbeeck","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21282_bb0040","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/jps.20392","article-title":"Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Ranitidine hydrochloride","volume":"94","author":"Kortej\u00e4rvi","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21282_bb0045","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/jps.20444","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Ibuprofen","volume":"94","author":"Potthast","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21282_bb0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/jps.20477","article-title":"Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS): Acetaminophen (paracetamol)","volume":"95","author":"Kalanzti","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21282_bb0055","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/jps.20615","article-title":"Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS): Amitryptiline hydrochloride","volume":"95","author":"Manzo","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21282_bb0060","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/jps.20614","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Cimetidine","volume":"95","author":"Jantratid","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21282_bb0065","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/jps.20765","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Isoniazid","volume":"96","author":"Becker","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21282_bb0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jps.20768","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Prednisolone","volume":"96","author":"Vogt","year":"2007","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21282_bb0075","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/jps.20817","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Prednisone","volume":"96","author":"Vogt","year":"2007","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21282_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/jps.20765","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Ethambutol dihydrochloride","author":"Becker","year":"2007","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21282_bb0085","article-title":"Martindale: The complete drug reference. Electronic version","year":"2005"},{"key":"10.1002\/jps.21282_bb0090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s002280050422","article-title":"Pharmacokinetics and pharmacodynamics of acetazolamide in patients with transient intraocular pressure elevation","volume":"54","author":"Yano","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/jps.21282_bb0095","first-page":"3","article-title":"Analytical profiles of drug substances and excipients","author":"Parasrampuria","year":"1993"},{"key":"10.1002\/jps.21282_bb0100","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1136\/bmj.1.5079.1122-c","article-title":"Acetazolamide and purpura","volume":"1","author":"Corbett","year":"1985","journal-title":"Br Med J"},{"key":"10.1002\/jps.21282_bb0105","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1001\/jama.1969.03160380096028","article-title":"Fatal pancytopenia and acetazolamide therapy","volume":"210","author":"Englund","year":"1969","journal-title":"JAMA"},{"key":"10.1002\/jps.21282_bb0110","first-page":"1500","article-title":"Acetazolamide-induced anaemia","volume":"1","author":"Niven","year":"1985","journal-title":"Med J"},{"key":"10.1002\/jps.21282_bb0115","series-title":"The United States Pharmacopeia\u2014The National Formulary","year":"2005"},{"key":"10.1002\/jps.21282_bb0120","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1021\/js960264c","article-title":"The polymorphic drug substances of the European Pharmacopoeia. Part 9. Physicochemical properties and crystal structure of acetazolamide crystal forms","volume":"86","author":"Griesser","year":"1997","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21282_bb0125","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jps.20302","article-title":"Trends in solubility of polymorphs","volume":"94","author":"Pudipeddi","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21282_bb0130","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1021\/jm00158a028","article-title":"N-Substituted sulfonamide carbonic anhydrase inhibitors with topical effects on intraocular pressure","volume":"29","author":"Duffel","year":"1986","journal-title":"J Med Chem"},{"key":"10.1002\/jps.21282_bb0135","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijpharm.2003.09.015","article-title":"Preparation and in vitro evaluation of Eudragit microspheres containing acetazolamide","volume":"269","author":"Haznedar","year":"2004","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.21282_bb0140","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/jps.2600790919","article-title":"Development of oral liquid dosage forms of acetazolamide","volume":"79","author":"Parasrampuria","year":"1990","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21282_bb0145","unstructured":"BP. 1980. Pharm. Eur. 4.00 Kommentar (German)."},{"key":"10.1002\/jps.21282_bb0150","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1016\/j.bmc.2004.07.049","article-title":"Theoretical study of gas-phase acidity, pKa, lipophilicity, and solubility of some biologically active sulfonamides","volume":"12","author":"Remko","year":"2004","journal-title":"Bioorg Med Chem"},{"key":"10.1002\/jps.21282_bb0155","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijpharm.2005.01.023","article-title":"Comparison of the octanol\/water partition coefficients calculated by ClogP\u00ae, ACDlogP and Kow Win\u00ae to experimentally determined values","volume":"294","author":"Machatha","year":"2005","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.21282_bb0160","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/mp034006h","article-title":"Molecular properties of WHO essential drugs and provisional biopharmaceutical classification","volume":"1","author":"Kasim","year":"2004","journal-title":"Mol Pharm"},{"key":"10.1002\/jps.21282_bb0165","unstructured":"WHO, Model List of Essential Medicines 13th edn. Available from URLwww.who.int\/medicines\/organization\/par\/edl\/expcom13\/eml13_en.doc"},{"key":"10.1002\/jps.21282_bb0170","unstructured":"FDA\/Center for Drug Evaluation and Research Office of Generic Drugs. Available from URLhttp:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/docs\/tempai.cfm."},{"key":"10.1002\/jps.21282_bb0175","unstructured":"Administraci\u00f3n Nacional de Medicamentos, Alimentos y Tecnolog\u00eda M\u00e9dica de la Rep\u00fablica Argentina. Available from URLhttp:\/\/www.anmat.gov.ar."},{"key":"10.1002\/jps.21282_bb0180","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/j.1552-4604.1998.tb05791.x","article-title":"Pharmacokinetics of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude","volume":"38","author":"Ritschel","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jps.21282_bb0185","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1001\/archopht.1982.01030040900006","article-title":"Effectiveness of generic acetazolamide","volume":"100","author":"Ellis","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"10.1002\/jps.21282_bb0190","first-page":"447","article-title":"Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics","volume":"58","author":"Schulz","year":"2003","journal-title":"Pharmazie"},{"key":"10.1002\/jps.21282_bb0195","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/jps.2600680323","article-title":"Nonlinear model for acetazolamide","volume":"68","author":"Kunka","year":"1979","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21282_bb0200","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1755-3768.1982.tb05778.x","article-title":"Monitoring acetazolamide treatment","volume":"60","author":"Alm","year":"1982","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"10.1002\/jps.21282_bb0205","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/10611860600720814","article-title":"Limited P-glycoprotein mediated efflux for anti-epileptic drugs","volume":"14","author":"Crowe","year":"2006","journal-title":"J Drug Target"},{"key":"10.1002\/jps.21282_bb0210","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jps.2600670233","article-title":"Bioavailability of acetazolamide tablets","volume":"67","author":"Yakatan","year":"1978","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21282_bb0215","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/bdd.2510030110","article-title":"Relative bioavailability of acetazolamide tablets","volume":"3","author":"Straughn","year":"1982","journal-title":"Biopharm Drug Dispos"},{"key":"10.1002\/jps.21282_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002018-199411010-00001","article-title":"Bioinequivaleance and drug toxicity. How great is the problem and what can be done?","volume":"11","author":"Gleiter","year":"1994","journal-title":"Drug Saf"},{"key":"10.1002\/jps.21282_bb0225","unstructured":"RoteListe\u00ae. Arzneimittelsverzeichnis f\u00fcr Deutschlandwww.rote-liste.de (assessed 24-10-2006)."},{"key":"10.1002\/jps.21282_bb0230","unstructured":"L\u00e6gemiddelstyrelsenwww.dkma.dk (assessed 24-10-2006)."},{"key":"10.1002\/jps.21282_bb0235","unstructured":"L\u00e4\u00e4kelaitoswww.nam.fi (assessed 24-10-2006)."},{"key":"10.1002\/jps.21282_bb0240","unstructured":"L'information de r\u00e9f\u00e9rence sur les produits de sant\u00e9www.vidal.fr (assessed 24-10-2006)."},{"key":"10.1002\/jps.21282_bb0245","unstructured":"Het College ter Beoordeling van Geneesmiddelenwww.cbg-meb.nl (assessed 24-10-2006)."},{"key":"10.1002\/jps.21282_bb0250","unstructured":"Statens l\u00e6kjemiddelverkwww.legemiddelverket.no (assessed 24-10-2006)."},{"key":"10.1002\/jps.21282_bb0255","unstructured":"FDA, Inactive Ingredient Databasehttp:\/\/www.fda.gov\/cder\/iig\/iigfaqWEB.htm#purpose (version date 03-10-2006)."},{"key":"10.1002\/jps.21282_bb0260","unstructured":"L\u00e4kemedelsverketwww.lakemedelsverket.se (assessed 24-10-2006)."},{"key":"10.1002\/jps.21282_bb0265","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/j.1552-4604.1998.tb04385.x","article-title":"When are bioavailability studies required? A German proposal","volume":"38","author":"Gleiter","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jps.21282_bb0270","unstructured":"College ter Beoordeling van Geneesmiddelen. Lijst vrijstelling bio-equivalentieonderzoek (positieve lijst) (List of APIs exempted from demonstration in vivo of bioequivalence when formulated in IR solid oral dosage forms)http:\/\/www.cbg-meb.nl\/nl\/reghoudr\/vrij.htm."},{"key":"10.1002\/jps.21282_bb0275","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0169-409X(00)00128-9","article-title":"Caco-2 monolayers in experimental and theoretical predictions of drug transport","volume":"46","author":"Artursson","year":"2001","journal-title":"Adv Drug Del Rev"},{"key":"10.1002\/jps.21282_bb0280","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1023\/A:1011919003030","article-title":"Correlation between oral drug absorption in humans and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: Comparison with the parental Caco-2 cell line","volume":"15","author":"Gres","year":"1998","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21282_bb0285","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1023\/B:PHAM.0000008037.57884.11","article-title":"Quantitative biopharmaceutics classification system: The central role of dose\/solubility ratio","volume":"20","author":"Rinaki","year":"2003","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21282_bb0290","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","article-title":"Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system","volume":"58","author":"Lindenberg","year":"2004","journal-title":"Eur J Pham Biopharm"},{"key":"10.1002\/jps.21282_bb0295","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","article-title":"Predicting drug disposition via application of BCS: Transport\/absorption\/elimination interplay and development of a biopharmaceutics drug disposition classification system","volume":"22","author":"Wu","year":"2005","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21282_bb0300","unstructured":"FDA, Code of Federal Regulations. Title 21, Part 320: Bioavailability and Bioequivalence requirements. Section 320.33. 2003www.accessdata.fda.gov."},{"key":"10.1002\/jps.21282_bb0305","unstructured":"PAHO, Science based criteria for bioequivalence in vivo and in vitro, biowaivers, and strategic framework for implementationwww.paho.org\/english\/ad\/ths\/ev\/be-doct-draft-eng.pdf."},{"key":"10.1002\/jps.21282_bb0310","unstructured":"FDA, 2005. Guidance for Industry. Immediate Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation. (SUPAC-IR).www.fda.gov\/cder\/guidance\/supac.htm."},{"key":"10.1002\/jps.21282_bb0315","unstructured":"European Commission, 2006. Guideline on Dossier requirements for Type IA and Type IB.http:\/\/ec.europa.eu\/enterprise\/pharmaceuticals\/eudralex\/vol-2\/c\/var_type_1a1b_guideline_06-2006.pdf."}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916326922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916326922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T17:31:57Z","timestamp":1557250317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916326922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":62,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0022354916326922"],"URL":"https:\/\/doi.org\/10.1002\/jps.21282","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}